Is the Debate on the Flecainide Action on the RYR2 in CPVT Closed?

Affiliations

Editorial

Jean-Pierre Benitah et al. Circ Res. 2021.

. 2021 Feb 5;128(3):332-334.

doi: 10.1161/CIRCRESAHA.121.318706. Epub 2021 Feb 4.

¹ Signaling and Cardiovascular Pathophysiology, UMR-S 1180, Inserm, Université Paris-Saclay, France.

No abstract available

Keywords: Editorials; arrhythmias; calcium; flecainide; heart diseases.

Comment on

RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
Kryshtal DO, Blackwell DJ, Egly CL, Smith AN, Batiste SM, Johnston JN, Laver DR, Knollmann BC. Kryshtal DO, et al. Circ Res. 2021 Feb 5;128(3):321-331. doi: 10.1161/CIRCRESAHA.120.316819. Epub 2020 Dec 10. Circ Res. 2021. PMID: 33297863 Free PMC article.

1. Salvage SC, Chandrasekharan KH, Jeevaratnam K, Dulhunty AF, Thompson AJ, Jackson AP, Huang CL. Multiple targets for flecainide action: implications for cardiac arrhythmogenesis. Br J Pharmacol. 2018;175:1260–1278. - PMC - PubMed
1. Lei M, Wu L, Terrar DA, Huang CL. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation. 2018;138:1879–1896. - PubMed
1. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA and Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380–3. - PMC - PubMed
1. Roston TM, Van Petegem F, Sanatani S. Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy. Curr Opin Cardiol. 2017;32:78–85. - PubMed
1. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10:1932–63. - PubMed